No longer just a Unilever PLC spin-out helping pharma reformulate drugs, Arecor Ltd. has now made the first moves to becoming a drug development company in its own right. With money in the bank from its latest fund raising, new institutional investors on board and a fresh Clinical Trial Application with the regulators, it may be Arecor’s moment to come out from the technology partnering shadows and put itself in the spotlight. CEO Sarah Howell talks to Scrip about the company's plans for developing its own diabetes drugs.
To date, Arecor’s business model has pivoted around its proprietary technology platform, Arestat, which reformulates products in development or already on the market and develops superior versions of those available
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?